GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Crescent Biopharma Inc (NAS:CBIO) » Definitions » EV-to-FCF

CBIO (Crescent Biopharma) EV-to-FCF : (As of Jul. 05, 2025)


View and export this data going back to 2025. Start your Free Trial

What is Crescent Biopharma EV-to-FCF?

EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Crescent Biopharma's Enterprise Value is $312.57 Mil. Crescent Biopharma does not have enough years/quarters to calculate its Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2024. Therefore, GuruFocus does not calculate Crescent Biopharma's EV-to-FCF at this moment.

The historical rank and industry rank for Crescent Biopharma's EV-to-FCF or its related term are showing as below:

CBIO' s EV-to-FCF Range Over the Past 10 Years
Min: -56.42   Med: 0   Max: 0
Current: -49.86
CBIO's EV-to-FCF is ranked worse than
100% of 396 companies
in the Biotechnology industry
Industry Median: 6.93 vs CBIO: -49.86

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.

As of today (2025-07-05), Crescent Biopharma's stock price is $15.89. Crescent Biopharma does not have enough years/quarters to calculate its Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2024. Therefore, GuruFocus does not calculate Crescent Biopharma's PE Ratio (TTM) at this moment.

Crescent Biopharma EV-to-FCF Historical Data

The historical data trend for Crescent Biopharma's EV-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Crescent Biopharma EV-to-FCF Chart

Crescent Biopharma Annual Data
Trend Dec24
EV-to-FCF
-

Crescent Biopharma Quarterly Data
Dec24
EV-to-FCF -

Competitive Comparison of Crescent Biopharma's EV-to-FCF

For the Biotechnology subindustry, Crescent Biopharma's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Crescent Biopharma's EV-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Crescent Biopharma's EV-to-FCF distribution charts can be found below:

* The bar in red indicates where Crescent Biopharma's EV-to-FCF falls into.


;
;

Crescent Biopharma EV-to-FCF Calculation

Crescent Biopharma's EV-to-FCF for today is calculated as:

EV-to-FCF=Enterprise Value (Today)/Free Cash Flow (TTM)
=312.571/
=

Crescent Biopharma  (NAS:CBIO) EV-to-FCF Explanation

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.

Crescent Biopharma's PE Ratio (TTM) for today is calculated as:

PE Ratio (TTM)=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=15.89/
=

Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.

Crescent Biopharma EV-to-FCF Related Terms

Thank you for viewing the detailed overview of Crescent Biopharma's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.

Crescent Biopharma Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Crescent Biopharma Inc (NAS:CBIO) » Definitions » EV-to-FCF
Comparable Companies
ALMS ATXS OLMA CYDY PRME NKTR LXRX CRVS OCGN HRTX VRTX ASX:CSL REGN XKRX:207940 ALNY XBRU:UCB XBRU:ARGX ONC XKRX:068270 BNTX
Traded in Other Exchanges
N/A
Address
221 Crescent Street, Suite 105, Building 23, Waltham, MA, USA, 02453
Website
https://www.crescentbiopharma.com
Crescent Biopharma Inc is a biopharmaceutical company developing novel therapeutics to treat solid tumors, led by CR-001, a proprietary anti-PD-1/anti-VEGF bispecific antibody. Crescent believes CR-001 has the potential to deliver improved clinical efficacy and safety over pembrolizumab. CR-001 is a new molecular entity designed to replicate the functional properties of ivonescimab, a cooperative bispecific anti-PD-1/anti-VEGF antibody in development by Akeso Biopharma and Summit Therapeutics that delivered improved efficacy in a head-to-head Phase 3 clinical trial versus Keytruda in non-small cell lung cancer. Crescent is advancing its second and third programs, CR-002 and CR-003, which are antibody drug conjugates (ADCs) against validated oncology targets.